Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Operating Expenses (2020 - 2026)

Maxcyte has reported Operating Expenses over the past 6 years, most recently at $16.9 million for Q4 2025.

  • Quarterly Operating Expenses fell 12.41% to $16.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.7 million through Dec 2025, down 4.86% year-over-year, with the annual reading at $78.7 million for FY2025, 4.86% down from the prior year.
  • Operating Expenses was $16.9 million for Q4 2025 at Maxcyte, down from $19.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $22.2 million in Q1 2024 and troughed at $10.7 million in Q2 2021.
  • The 5-year median for Operating Expenses is $19.3 million (2024), against an average of $18.1 million.
  • Year-over-year, Operating Expenses skyrocketed 60.38% in 2022 and then fell 12.96% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $13.9 million in 2021, then increased by 26.99% to $17.6 million in 2022, then increased by 25.87% to $22.2 million in 2023, then fell by 12.96% to $19.3 million in 2024, then dropped by 12.41% to $16.9 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Operating Expenses are $16.9 million (Q4 2025), $19.4 million (Q3 2025), and $21.2 million (Q2 2025).